TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Advocacy Intervention for HIV-Positive African Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older;~* self-identify as African American or Black~* client of APLA~* they are on ART and missed at least 1 dose in the past month~* they have a currently detectable or unknown HIV viral load (or have not had a viral load test within the last six months).~Exclusion Criteria:~* received treatment advocacy in last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wait-list control (Type: NO_INTERVENTION): Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
- treatment advocacy (Type: EXPERIMENTAL): Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vasculaire Compression System Increases Flow Velocity in the Femoral Vein

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 years old and 65 years old;~* Capable of and willing to lay supine for approximately one hour;~* Subjects must provide written informed consent~Exclusion Criteria:~* History of Deep Vein Thrombosis (DVT) or suspected DVT;~* History of vascular disease, e.g. coronary or peripheral artery disease;~* History of stroke;~* History of pulmonary edema;~* History of congestive heart failure;~* Diabetes mellitus;~* Past or present smoker;~* Surgery or trauma to the right leg within the last six months;~* Open ulcers or wounds on the right leg;~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients, \>=18 years of age;~* HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;~* candidates for chemotherapy.~Exclusion Criteria:~* previous chemotherapy for metastatic or locally recurrent breast cancer;~* concomitant hormonal therapy for metastatic or locally recurrent disease;~* concomitant Herceptin therapy for treatment of metastatic or locally recurrent HER-2 positive disease;~* previous radiotherapy for treatment of metastatic disease;~* evidence of CNS metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-~Subjects must meet all of the following inclusion criteria:~* Age 30-75 years~* LDL-cholesterol = 115 -190 mg/dL~* Triglycerides \< 400 mg/dL~* Any cardiovascular therapy should be stable for type and dose for at least three months~* Signed, written informed consent~Exclusion Criteria:~-~Subjects must meet none of the following exclusion criteria:~* Intolerance to any ingredient of dietary supplement~* Patients already suffering from cardiovascular diseases or at high risk of developing cardiovascular diseases~* Myopathies~* Uncontrolled diabetes mellitus based on PI judgment~* Chronic renal failure \[defined as estimated glomerular filtration rate (eGFR) \<60ml/min/1.73m2\] or liver failure \[defined as aspartate aminotransferase (AST) and /or Alanine Aminotransferase (ALT) \>3 upper limit of normal (ULN)\]~* Body Mass Index \> 32 kg/m2~* Therapy with statins or other drugs or supplements with effects on lipid metabolism~* Patients with acquired immunodeficiency~* Treatment with immunosuppressants~* Pregnant or breastfeeding women~* Women of childbearing potential not willing to use effective birth control methods~* Patients participating or having participated in another clinical trial within the previous 3 months~* Current or recent history of drug or alcohol addiction based on PI judgment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Nutraceutical combination (Type: EXPERIMENTAL): One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
- Placebo (Type: PLACEBO_COMPARATOR): One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT~* 14-65 years~Exclusion Criteria:~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF + Decitabine + BUCY (Type: EXPERIMENTAL): For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
- BUCY (Type: ACTIVE_COMPARATOR): For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identification as a transgender individual \[As determined by the two-step process of gender identification whereby potential participants will be asked their gender identity and sex assigned at birth\]~* HIV-uninfected by EIA and viral load within 7 days of study entry~* Creatinine clearance ≥ 60 mL/min by Cockroft Gault for ages ≥18 years (Schwartz equation for those \<18)~* Willing to comply with all study procedures~* On a stable dose of cs-HT for at least 2 months verified by clinical chart review and willing to not change doses for duration of PK study~Exclusion Criteria:~* Hospitalization within 30 days of study entry (elective procedures okay with team approval)~* Condition (medical, psychological, or social) that, in the opinion of the study investigators, would preclude the participant from completing study-required procedures~* Previous participation in an HIV vaccine study, unless the participant can document placebo arm assignment~* Use of TDF/FTC in the past 3 months

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- TDF/FTC and cs-HT (Type: EXPERIMENTAL): Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 2 years to \<13-year-old~2. Uncomplicated falciparum malaria as defined as:~   * Positive blood smear with asexual forms of P. falciparum (may be mixed with non-falciparum species)~  * Parasitaemia between 5,000-250,000 parasites/µL~  * Fever defined as tympanic temperature \>37.5°C or history of fever within last 48 hours~3. Ability to take oral medication~4. Willingness and ability to comply with study protocol for study duration~5. Written informed consent given to participate in the trial~Exclusion Criteria:~1. Signs of severe/complicated malaria\*~2. Any clinical reason suggesting that the child's treatment should be given immediately and not delayed during the transfer to Kilifi County Hospital in the opinion of the treating physician.~3. Acute illness other than malaria requiring urgent systemic treatment as assessed by the treating physician~4. Previous splenectomy~5. Treatment with artemisinin or ACT within the previous 7 days~6. Treatment with mefloquine in the 2 months prior to presentation~7. Known hypersensitivity or contraindication to arterolane-piperaquine, DHA-piperaquine, artemisinin, mefloquine (epilepsy, major psychiatric illness) or primaquine~8. QTc interval \>450 milliseconds at point of presentation~9. Known personal or family history of cardiac conduction problems~10. Participation within another clinical trial in the previous 3 months

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Arterolane-piperaquine (Type: ACTIVE_COMPARATOR): Arterolane-piperaquine for 3 days
- Arterolane-piperaquine+mefloquine (Type: ACTIVE_COMPARATOR): Arterolane-piperaquine + mefloquine for 3 days
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or Child bearing potential, has a negative urine pregnancy test at Visit 1, and agrees to use acceptable contraceptive methods used consistently and correctly~* Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)~* Current or former smokers with a history of at least 10 pack-years of cigarette smoking.~* At Visit 1, FEV1/FVC ratio must be \<0.70~* At Visit 1, post-bronchodilator FEV1must be \>30% and \<80% predicted normal value, calculated using The Third National Health and Nutrition Examination Survey (NHANES III) reference equations.~Exclusion criteria:~* Significant diseases other than COPD, i.e., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.~* Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.~* Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.~* Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).~* Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).~* Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated.~* Subjects who have a history of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GP MDI (PT001) 14.4 μg (Type: EXPERIMENTAL): Glycopyrronium
- FF MDI (PT005) 9.6 μg (Type: EXPERIMENTAL): Formoterol Fumarate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C infection for at least 6 months duration~* Hepatitis C genotype 1a or 1b~* Participants must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study~* Participants showed a previous null response to therapy as defined by \< 2 logarithm to the base 10 (log10) international units per milliliter (IU/mL) decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV~Exclusion Criteria:~* Hepatitis C infection with a genotype other than genotype 1a or 1b~* Body mass index \< 18 or \>= 36 kilograms per square meters (kg/m\^2)~* Hepatitis A, hepatitis B, or human immunodeficiency virus (HIV) infection~* Herbal remedies \<=1 month prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
- TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
- TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks) (Type: EXPERIMENTAL): Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
- TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks) (Type: ACTIVE_COMPARATOR): Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with potential diagnosis of ovarian, fallopian, or primary peritoneal cancer.~2. Care plan including surgical debulking and traditional adjuvant or neo-adjuvant chemotherapy (6-9 cycles of platinum and taxane based therapy).~3. Eastern Cooperative Oncology Group performance status 0-2.~4. Age \> 18 years or \< 80 years.~5. Adequate renal function (serum creatinine \<1.4mg/dL).~6. Adequate liver function (bilirubin \< 1.5 times ULN).~   * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \< 5 times the upper limit of normal in case of liver metastases.~  * ALT or AST \< 2.5 times the ULN in absence of liver metastases.~7. Ability to understand and complete written informed consent.~8. Mentally, physically, and geographically able to undergo treatment and follow up.~Exclusion Criteria:~1. Patients diabetes mellitus. (Patients with only a history of gestational diabetes will be allowed to be included in the study.)~2. Metformin use in the last 6 months.~3. A known hypersensitivity to metformin.~4. A history of metabolic acidosis, including ketoacidosis or increased risk of lactic acidosis.~5. Pregnancy or Lactation.~6. Patients who have any severe and/or uncontrolled medical conditions.~7. Patients with a history of renal disease.~8. Patients with other known active malignancy (excluding adequately treated basal cell / squamous cell skin cancer, in situ cancer, or other cancer for which the patient has been disease free for 2 years).~9. Patients receiving any other investigational agents.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Substance P Antagonists on Adrenal Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects;~* Age ranging 18 - 30 years old;~* Submitted to a social security regimen;~* Agreeing to the study \& Informed consent form signed;~* Body mass index (\[weight (kg)/height (m)\]²) \< 27;~* No treatment received 6 weeks before inclusion;~* No anomaly after: complete clinical examination, pulse and blood pressure measurement, ECG;~* No biological abnormality after the following biological testing:~  * Hematology: white \& red blood cells \& platelets count, haemoglobin, hematocrit~ * Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea~ * Urinary biochemistry (24 h collection): cortisol, aldosterone~ * Serologies: HIV, HBV, HCV~* No participation in a clinical trial 3 months before inclusion.~Exclusion Criteria:~* Subject not agreeing to the study or impossible to follow-up;~* Known history of significant medical or surgical pathology, notably endocrine;~* Renal or hepatic insufficiency;~* Nephrotic syndrome;~* Edematous syndrome;~* Hypertension or postural hypotension;~* Cardiac rhythm or conduction pathologies;~* Cardiac insufficiency;~* Epilepsy;~* Significant psychiatric disorder;~* Known history of severe allergy, hypersensitivity to aprepitant ant/or metoclopramide;~* Hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficit;~* Impaired lactose tolerance.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): 7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
- placebo (Type: PLACEBO_COMPARATOR): 7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete